Erivedge: new skin cancer drug and first Hedgehog pathway inhibitor

Erivedge (vismodegib) has been launched by Roche for the treatment of advanced basal cell carcinoma (BCC).

by
Erivedge (vismodegib) is administered once daily until disease progression or unacceptable toxicity occurs.
Erivedge (vismodegib) is administered once daily until disease progression or unacceptable toxicity occurs.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package